-
CAFs-Secreted Fatty Acids Drive Oral Cancer via Lipid Raft F
2026-06-09
This study reveals how cancer-associated fibroblasts (CAFs) in the tumor microenvironment fuel oral squamous cell carcinoma (OSCC) progression through fatty acid secretion. The work uncovers a mechanistic link between CAF-derived free fatty acids, lipid raft assembly, and the activation of oncogenic PI3K/AKT signaling, highlighting new potential therapeutic targets in oral cancer.
-
Bradford Protein Assay Kit: Rapid, Sensitive Protein Quantif
2026-06-09
The Bradford Protein Assay Kit (SKU K4103) provides a rapid, sensitive method for quantifying protein concentrations in solution, making it well-suited to routine workflows in molecular biology and protein research. It is optimal for samples free of interfering detergents and is not recommended for absolute quantification of atypical or highly modified proteins.
-
EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Mechanism & Evide
2026-06-08
EZ Cap™ Firefly Luciferase mRNA (5-moUTP) is a chemically modified, in vitro transcribed mRNA designed for robust bioluminescent reporter assays and enhanced mRNA delivery. Its Cap 1 structure and 5-methoxyuridine modifications optimize translation and minimize innate immune activation. This article details its molecular rationale, validated performance, and protocol integration.
-
Tunicamycin: A Benchmark N-Glycosylation Inhibitor for ER St
2026-06-08
Tunicamycin is a potent N-glycosylation inhibitor widely used to induce endoplasmic reticulum (ER) stress and study unfolded protein response mechanisms. Its precise action on glycoprotein synthesis makes it a critical tool for dissecting inflammation suppression in macrophages and protein homeostasis pathways.
-
Phosbind Biotin LC: Technical Guide for Western Blot Phospho
2026-06-07
Phosbind Biotin LC addresses the challenge of detecting phosphorylated proteins on PVDF membranes when phospho-specific antibodies are unavailable or insufficient. It enables sequence-independent identification in Western Blot workflows but is not suitable for aqueous-only protocols or long-term storage in solution.
-
ABT-263 (Navitoclax) in Apoptosis and Senescence Research
2026-06-06
ABT-263 (Navitoclax) empowers researchers to dissect apoptotic mechanisms and senescence, bridging cancer biology with cutting-edge epigenetic age profiling. This guide delivers actionable workflows, troubleshooting strategies, and protocol optimizations for maximizing the compound’s impact in apoptosis assays and translational oncology.
-
BMS-345541: IKK-1/IKK-2 Inhibitor for Advanced Inflammation
2026-06-05
BMS-345541 (free base) is a selective IKK-1/IKK-2 inhibitor that enables precise NF-κB pathway modulation in inflammation and cancer research. Its unique allosteric inhibition and proven efficacy in cytokine suppression and apoptosis induction make it essential for dissecting disease mechanisms and therapeutic strategies.
-
Amitriptyline HCl: Protocol and QC Guidance for Neuropharmac
2026-06-05
Amitriptyline HCl is a high-purity tricyclic compound for modulating serotonin, norepinephrine, and related neurotransmitter receptors in neuropharmacology and mood disorder research. It is best used for receptor-binding and mechanistic assays that demand precise solubility and short-term solution stability. Researchers should avoid applications requiring extended compound stability or unsupported mechanistic extrapolation.
-
Concanavalin A Targets Conserved N-Glycans to Inhibit Corona
2026-06-04
Guo et al. reveal that concanavalin A (ConA) binds phylogenetically conserved N-linked glycans on coronavirus spike proteins, broadly inhibiting viral entry and membrane fusion. This study identifies invariant glycosylation sites as promising targets for pan-coronavirus therapeutics, with implications for overcoming viral escape from antibody-based interventions.
-
Prestained Protein Marker (Triple color, EDTA free, 10-250 k
2026-06-04
The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) addresses the need for reliable, visible molecular weight standards in SDS-PAGE and Western blotting, especially for workflows requiring EDTA-free reagents or fluorescent imaging compatibility. It is not intended for direct protein quantitation or as an enzymatic activity standard.
-
2,5-di-tert-butylbenzene-1,4-diol: Precision in Calcium Sign
2026-06-03
2,5-di-tert-butylbenzene-1,4-diol (BHQ) empowers researchers to precisely manipulate endoplasmic reticulum calcium dynamics, advancing stem cell mobilization and vascular physiology studies. This article details proven workflows, troubleshooting strategies, and the transformative impact of BHQ in SERCA-mediated experiments.
-
Polymyxin B Sulfate: Applied Workflows in Infection Research
2026-06-03
Polymyxin B sulfate stands out as a gold standard for targeting multidrug-resistant Gram-negative bacteria, but its immunomodulatory properties now drive innovation in immune-microbiota and sepsis models. This article translates the latest research into actionable protocols, troubleshooting strategies, and advanced comparative use-cases leveraging APExBIO's C3090 Polymyxin B (sulfate).
-
ECL Chemiluminescent Substrate Detection Kit: Hypersensitive
2026-06-02
The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) empowers researchers to detect ultra-low-abundance proteins on nitrocellulose and PVDF membranes with extended signal duration and minimal background. Leveraging HRP chemiluminescence, this kit optimizes Western blotting for high-sensitivity applications, as demonstrated by its role in cutting-edge neurobiology research.
-
Chlorpromazine HCl: Dopamine Receptor Antagonist in Research
2026-06-02
Chlorpromazine HCl is a phenothiazine dopamine receptor antagonist widely used in psychotic disorder and neuropharmacology research. It functions by competitively inhibiting dopamine receptors and serves as a critical tool for dissecting clathrin-mediated endocytosis. This article provides atomic, evidence-based guidance for experimental use and caveats.
-
Resibufogenin Inhibits NLRP3 Inflammasome to Mitigate Athero
2026-06-01
This study demonstrates that resibufogenin (RBG) effectively attenuates atherosclerosis in ApoE-/- mice by inhibiting NLRP3 inflammasome assembly, reducing inflammation and plaque development. The findings provide mechanistic insight into RBG's interaction with NLRP3 and highlight its potential as a therapeutic strategy for cardiovascular inflammation.